New Caffeic Acid Derivatives as Antimicrobial Agents: Design, Synthesis, Evaluation and Docking. 2019

Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
TSMU I.Kutateladze Institute of Pharmacochemistry, Tbilisi, 0159, Georgia.

BACKGROUND Phenolic acids (caffeic-, ferulic and p-coumaric acid) are widely distributed in the plant kingdom and exhibit broad spectrum of biological activities, including antimicrobial activity. OBJECTIVE The goal of this paper is the synthesis of some caffeic acid derivatives selected based on computer-aided predictions and evaluate their in vitro antimicrobial properties against Gram positive and Gram negative bacteria and also a series of fungi. METHODS In silico prediction of biological activity was used to identify the most promising structures for synthesis and biological testing, and the putative mechanisms of their antimicrobial action. The designed compounds were synthesized using classical organic synthesis methods. The antimicrobial activity was studied using microdilution method. RESULTS Twelve tested compounds have shown good antibacterial activity. Five out of twelve tested compounds appeared to be more active than the reference drugs ampicillin and streptomycin. Despite that all compounds exhibited good activity against all bacteria tested, the sensitivity of bacteria towards compounds in general was different. The evaluation of antifungal activity revealed that all compounds were more active than ketoconazole, while seven compounds (2, 3, 4, 5, 7, 8 and 12) appeared to be more active than bifonazole. Docking results indicate that gyrase inhibition is the putative mechanism of antibacterial action while the inhibition of 14α-demethylase may be responsible for antifungal action. Prediction of cytotoxicity by PROTOX showed that compounds are not toxic (LD50 1000-2000 mg/kg). CONCLUSIONS Thirteen compounds, from which six are new ones, were synthesized, and twelve compounds were tested for antimicrobial activity. The studied compounds appeared to be promising potent and non-toxic antimicrobials, which could be considered as leads for new pharmaceutical agents.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002109 Caffeic Acids A class of phenolic acids related to chlorogenic acid, p-coumaric acid, vanillic acid, etc., which are found in plant tissues. It is involved in plant growth regulation. Acids, Caffeic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
September 2015, Bioorganic & medicinal chemistry,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
October 2019, Antibiotics (Basel, Switzerland),
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
February 2022, Research in pharmaceutical sciences,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
September 2020, Bioorganic & medicinal chemistry letters,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
April 2024, Heliyon,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
January 2015, Medicinal chemistry (Shariqah (United Arab Emirates)),
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
July 2019, Archiv der Pharmazie,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
June 2023, BMC chemistry,
Maia Merlani, and Vakhtang Barbakadze, and Lela Amiranashvili, and Lali Gogilashvili, and Vladimir Poroikov, and Anthi Petrou, and Athina Geronikaki, and Ana Ciric, and Jasmina Glamoclija, and Marina Sokovic
December 2023, RSC medicinal chemistry,
Copied contents to your clipboard!